Zetta Genomics Zetta Genomics developed XetaBase, a platform for managing and analyzing genomic and multiomic data at population scale. Built on the open-source OpenCB platform, it loads, normalizes, indexes, annotates and queries genetic variants, supporting repeated interpretation as scientific evidence changes. Healthcare organizations, researchers and life sciences companies use it for clinical and research workflows, including biomarker discovery and precision medicine. A Cambridge University and Genomics England spinout, its key assets were acquired by TriNetX on April 7, 2026; TriNetX continues supporting existing XetaBase customers and integrating the technology with its federated clinical-data network.
Founded 2018
team@apexlogos.ai · 18 hours ago
Zetta Genomics Limited, company number 11475418, is distinct from native Zetta, ZettaCom and ZettaBlock. The company’s own milestone lists its launch in 2018; other primary releases give inconsistent 2017 or 2019 founding years. https://zettagenomics.com/about-us/
The February 8, 2024 issuer release announces GBP 1.8 million of additional second-seed funding, following GBP 1.9 million in April 2023 and GBP 2.5 million in February 2022. Co-investor We Venture Capital reports a EUR 4.3 million seed-extension round and explicitly names Nova Capital, Nina Capital and Cambridge Enterprise; the issuer also names APEX Ventures. One dated seed extension is recorded with amount unknown because the incremental versus aggregate scope has not been reconciled. Both raw primary claims are retained, without adding them or inventing a currency conversion. Only verified existing investors are linked. Lead investor We Venture Capital requires a complete manager profile before linkage. https://www.einpresswire.com/article/686915168/zetta-genomics-expands-second-seed-funding-round-with-additional-1-8-million https://weventurecapital.com/new-investment-in-zetta-genomics/
TriNetX’s April 7, 2026 release confirms acquisition of key assets and continued support for existing XetaBase customers. It does not prove a whole-company merger, transaction price or new startup financing. We Venture Capital separately reports its April 2026 exit. The nine leaders remain published on Zetta’s own roster; continued appointments after the acquisition are unconfirmed. Anthony Vallance-Owen’s investor biography explicitly qualifies his Zetta board seat as prior to exit. Louise Warme is an observer, not a director. Ignacio Medina, Nacho Medina and Ignacio Medina Castello refer to the same founder, whose full name appears in the buyer’s release. Older CEO appointments of Will Spooner and Mark Bailey are not imported as current. https://trinetx.com/press-releases/trinetx-enhances-its-ability-to-federate-genomics-data-across-its-global-network-of-providers-through-the-acquisition-of-key-assets-of-zetta-genomics/ https://weventurecapital.com/we-vc-announces-exit-of-zetta-genomics-in-trinetx-acquisition/ https://weventurecapital.com/meet-the-team/ SHOW MORE
